GlassScriptPhysician profile
Crystal Marie Cooper
NPI 1609566413
$2,036.07
in general payments reported to CMS, 2019-2025
26 companies · $928 in 2025
The $928 reported for 2025 was more than what 86% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $363 · 2024: $745 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,036.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $420.86 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $348.56 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Corcept Therapeutics | $181.30 | 2023-2025 | Korlym |
| Abbvie INC. | $147.87 | 2023-2025 | |
| Radius Health, INC. | $118.67 | 2023-2025 | Tymlos |
| Averitas Pharma INC. | $75.42 | 2023-2025 | Qutenza |
| Xeris Pharmaceuticals, INC. | $75.33 | 2023-2024 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $68.87 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.21 | 2023-2025 | Jardiance, Synjardy |
| Amphastar Pharmaceuticals, INC. | $49.91 | 2023-2024 | Baqsimi |
| Amgen INC. | $46.34 | 2024-2025 | Tepezza |
| Amneal Pharmaceuticals LLC | $45.00 | 2023-2025 | Unithroid |
| Sequel Med Tech, LLC | $40.72 | 2025 | Twiist |
| Recordati_rare_diseases_inc. | $40.65 | 2025 | Isturisa |
| Tandem Diabetes Care, INC. | $40.25 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $34.37 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Acella Pharmaceuticals, LLC | $33.79 | 2023-2025 | NP Thyroid 60 |
| Boston Scientific Corporation | $33.35 | 2023-2024 | Lux-Dx Insertable Cardiac Monitor |
| Cequr Corporation | $27.28 | 2024-2025 | Cequr Simplicity |
| Insulet Corporation | $25.64 | 2024 | Omnipod |
| Antares Pharma, INC. | $25.03 | 2024 | Xyosted |
| Pacira Pharmaceuticals Incorporated | $22.52 | 2024 | Exparel |
| Glaxosmithkline, LLC. | $20.68 | 2025 | Arexvy, Shingrix |
| Tolmar, INC. | $16.39 | 2025 | Jatenzo |
| Dexcom, INC. | $15.47 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $13.59 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.